Free shipping on all orders over $ 500

Vepdegestrant (ARV-471)

Cat. No. M21158

All AbMole products are for research use only, cannot be used for human consumption.

Vepdegestrant (ARV-471) Structure
Synonym:

ARV471; PF-07850327

Size Price Availability Quantity
1mg USD 180 In stock
5mg USD 450 In stock
10mg USD 640 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Vepdegestrant (ARV-471) is an oral estrogen receptor PROTAC protein degrader for breast cancer. Vepdegestrant (ARV-471) is a heterobifunctional molecule that promotes the interaction between estrogen receptor alpha and intracellular E3 ligase complexes. Vepdegestrant (ARV-471) causes ubiquitination and subsequent degradation of the estrogen receptor via the proteasome. Vepdegestrant (ARV-471) potently degrades ER-positive The ER in breast cancer cell lines is potently degraded by ARV-471 with a DC50 value of approximately 2 nM.

Chemical Information
Molecular Weight 723.9
Formula C45H49N5O4
CAS Number 2229711-68-4
Solubility (25°C) DMSO 90 mg/mL
Storage -20°C, protect from light, dry, sealed
References

[1] Jia-Yue Xi, et al. Bioorg Chem. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery

[2] Diego Garcia Jimenez, et al. ADMET DMPK. Are we ready to design oral PROTACs®?

[3] Hui Qin, et al. Curr Med Chem. Overview of PROTACs Targeting the Estrogen Receptor: Achievements for Biological and Drug Discovery

[4] Chao Wang, et al. Eur J Med Chem. Developments of CRBN-based PROTACs as potential therapeutic agents

[5] Si-Min Qi, et al. Front Pharmacol. PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Related PROTAC Products
CR8

CR8 is a potent and selective inhibitor of cyclin dependent kinase (CDK1, 2, 5, 7, and 9).

ARV-393

ARV-393 is an orally active PROTAC degrader targeting BCL6 for studies related to diffuse large B-cell lymphoma. ARV-393 utilizes the ubiquitin-proteasome system to target the degradation of BCL6.

ARV-766

ARV-766 is an orally active and potent proteolysis targeting chimera (PROTAC) protein degrader. ARV-766 degrades wild-type androgen receptor (AR) but also relevant AR LBD mutants, including the most prevalent AR L702H, H875Y, and T878A mutations. ARV-766 has the potential to be first- and best-in class PROTAC AR degrader in mCRPC.

Indisulam

Indisulam is a carbonic anhydrase inibitor and antitumor CDK inhibitor. Indisulam targets the G1 phase of the cell cycle by depleting cyclin E. inducing p53 and p21, and inhibiting CDK2, causing a blockade in the G1/S transition.

dBET6

dBET6 is a highly potent, selective and cell-permeable PROTAC connected by ligands for Cereblon and BET, with an IC50 of 14 nM, and has antitumor activity.

  Catalog
Abmole Inhibitor Catalog




Keywords: Vepdegestrant (ARV-471), ARV471; PF-07850327 supplier, PROTAC, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.